Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 548 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

EDUCATIONAL FORUM

Use of Bayesian statistics in drug development: Advantages and challenges

Gupta Sandeep K

Year : 2012| Volume: 2| Issue : 1 | Page no: 3-6

   This article has been cited by
 
1 Gingyogedokusan versus oseltamivir for the treatment of influenza: Bayesian inference using the Markov chain Monte Carlo method with prior pilot study data
Kentaro Iwata,Takashi Nishimoto,Kumi Higasa,Seiichiro Usuki,Chisato Miyakoshi
Traditional & Kampo Medicine. 2019;
[Pubmed]  [Google Scholar] [DOI]
2 Promising Results from Alzheimer’s Disease Passive Immunotherapy Support the Development of a Preventive Vaccine
D. J. Marciani
Research. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
3 Alirocumab, Decreased Mortality, Nominal Significance, P Values, Bayesian Statistics, and the Duplicity of Multiplicity
Harold Edward Bays
Circulation. 2019; 140(2): 113
[Pubmed]  [Google Scholar] [DOI]
4 Artificial Intelligence in Clinical Health Care Applications: Viewpoint
Michael van Hartskamp,Sergio Consoli,Wim Verhaegh,Milan Petkovic,Anja van de Stolpe
Interactive Journal of Medical Research. 2019; 8(2): e12100
[Pubmed]  [Google Scholar] [DOI]
5 Pediatric Heart Failure: An Evolving Public Health Concern
Stephanie J. Nakano,Shelley D. Miyamoto,Jack F. Price,Joseph W. Rossano,Antonio G. Cabrera
The Journal of Pediatrics. 2019;
[Pubmed]  [Google Scholar] [DOI]
6 Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach
Annette Kopp-Schneider,Manuel Wiesenfarth,Ruth Witt,Dominic Edelmann,Olaf Witt,Ulrich Abel
Biometrical Journal. 2018;
[Pubmed]  [Google Scholar] [DOI]
7 Bayesian adaptive trials for rare cardiovascular conditions
Azadeh Shohoudi,David A Stephens,Paul Khairy
Future Cardiology. 2018; 14(2): 143
[Pubmed]  [Google Scholar] [DOI]
8 Evolving paradigms for new agent development in pediatric oncology
Andrea Flynn,Elizabeth Fox
Current Opinion in Pediatrics. 2018; 30(1): 10
[Pubmed]  [Google Scholar] [DOI]
9 Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle
Imke H. Bartelink,Ella F. Jones,Sheerin K. Shahidi-Latham,Pei Rong Evelyn Lee,Yanan Zheng,Paolo Vicini,Laura van ‘t Veer,Denise Wolf,Andrei Iagaru,Deanna L. Kroetz,Brendan Prideaux,Cornelius Cilliers,Greg M. Thurber,Zena Wimana,Geraldine Gebhart
Clinical Pharmacology & Therapeutics. 2018;
[Pubmed]  [Google Scholar] [DOI]
10 Rationale of a Novel Study Design for the BIOFLOW V Study, a Prospective, Randomized Multicenter Study to Assess the Safety and Efficacy of the Orsiro Sirolimus-Eluting Coronary Stent System Utilizing a Bayesian Approach
Gheorghe Doros,Joseph M. Massaro,David E. Kandzari,Ron Waksman,Jacques J. Koolen,Donald E. Cutlip,Laura Mauri
American Heart Journal. 2017;
[Pubmed]  [Google Scholar] [DOI]
11 Integration of PKPD relationships into benefit-risk analysis
Francesco Bellanti,Rob C. van Wijk,Meindert Danhof,Oscar Della Pasqua
British Journal of Clinical Pharmacology. 2015; 80(5): 979
[Pubmed]  [Google Scholar] [DOI]
12 Trends in epidemiology in the 21st century: time to adopt Bayesian methods
Edson Zangiacomi Martinez,Jorge Alberto Achcar
Cadernos de Saúde Pública. 2014; 30(4): 703
[Pubmed]  [Google Scholar] [DOI]

 

Read this article